Every Form 4 that Sight Sciences, Inc. (SGHT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SGHT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGHT filings page.
Sight Sciences, Inc. (SGHT) reported that its Chief Legal Officer, the reporting person in this Form 4, received an equity compensation award. The officer was granted 181,818 restricted stock units (RSUs) of common stock for no cash consideration, increasing the officer’s directly held common stock-related position to 181,818 shares on an as-converted basis.
The RSUs were granted under Sight Sciences’ 2021 Incentive Award PlanAugust 10, 2027 and continuing through August 10, 2030, subject to the officer’s continued service with Sight Sciences on each vesting date. Each RSU represents a contingent right to receive one share of Sight Sciences common stock.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 12,733 shares of common stock, with a weighted average price of $5.51 per share. According to the disclosure, these shares were sold solely to cover his tax liability arising from the vesting of restricted stock units.
After this tax-related sale, Hayden holds 357,037 shares tied to Sight Sciences, including 100,015 shares of common stock and 257,022 shares that are scheduled to be received as restricted stock units vest in the future. The transaction reflects routine tax withholding rather than a discretionary reduction in his overall stake.
Sight Sciences Chief Financial Officer James Rodberg reported an open-market sale of 6,902 shares of common stock on July 2, 2026 at a weighted average price of $5.36 per share, in transactions ranging from $5.19 to $5.46. According to the footnotes, these shares were sold to cover his tax liability arising from the vesting of restricted stock units. Following the sale, he beneficially owns 224,037 shares, including 55,200 shares of common stock and 168,837 shares that will be acquired upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Chief Technology Officer David Badawi reported an open-market sale of 7,418 shares of common stock at a weighted average price of $5.508 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi directly held 1,982,872 shares of common stock and related equity, including 1,813,950 shares of common stock and 168,922 shares that will be acquired upon future vesting and settlement of unvested RSUs. The transaction represents a small portion of his overall equity position.
Sight Sciences EVP of Operations & R&D Taylor Brenton reported a small open-market sale of company stock primarily to cover taxes on vesting equity. Brenton sold 2,829 shares of common stock at a weighted average price of $5.42 per share in multiple transactions.
The shares were sold to satisfy tax liabilities arising from the vesting of restricted stock units rather than as a discretionary portfolio move. After these sales, Brenton’s reported holdings total 264,978 shares, including 36,696 shares of common stock and 228,282 shares that will be received upon future RSU vesting and settlement.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported an open-market sale of 24,184 shares of common stock at a weighted average price of $5.36 per share. According to the disclosure, the sale was made to cover her tax liability arising from the vesting of restricted stock units. After this transaction, she holds a total of 664,709 shares, including 192,669 shares of common stock and 472,040 shares subject to unvested restricted stock units that may be acquired upon future vesting and settlement.
Sight Sciences, Inc. President and CEO Paul Badawi reported an open-market sale of 28,684 shares of Common Stock at a weighted average price of $5.42 per share. According to the filing, the shares were sold to cover his tax liability arising from the vesting of restricted stock units (RSUs).
After this tax-related sale, Badawi holds a total of 6,122,472 shares, consisting of 5,572,746 shares of Common Stock and 549,726 additional shares that will be issued upon future vesting and settlement of unvested RSUs. The transaction represents only a small portion of his overall equity position.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 14,100 shares of Common Stock at a weighted average price of $4.879 per share. After this trade, he directly holds 1,434,283 shares, including 28,261 restricted stock units subject to vesting as previously reported.
He also reports indirect interests in 5,086,920 shares held by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust, where he is a trustee, and 632,456 shares held by Allegro Investment Fund, L.P. He disclaims beneficial ownership of Allegro’s shares and of the trust and fund holdings beyond any pecuniary interest.
Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Tamara Fountain received an equity grant in the form of restricted stock units. She was awarded 28,261 RSUs on June 4, 2026 under the company’s Non-Employee Director Compensation Program, representing approximately $130,000 of common stock based on the closing price that day.
The RSUs vest on the earlier of June 4, 2027 and the company’s 2027 annual meeting of stockholders, subject to her continued board service. Following this grant, she holds 109,650 shares and units in total, including 81,389 shares of common stock and 28,261 unvested RSUs.
Encrantz Staffan reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Staffan Encrantz received an equity award in the form of restricted stock units (RSUs). He was granted 28,261 RSUs under the company’s Non-Employee Director Compensation Program, with the number of units based on approximately $130,000 of common stock at the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, contingent on his continued board service. Following this grant, his direct holdings include 1,391,922 shares of common stock plus the 28,261 RSUs, totaling 1,420,183 shares. Additional indirect positions are reported through the 1997 Staffan and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., with beneficial ownership of those shares disclaimed as described in the footnotes.
Burbach Gerhard F reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences, Inc. reported that director Gerhard F. Burbach received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award equals approximately $130,000 of common stock based on the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, if he continues serving as a director through that date. Following this grant, he directly holds a total of 123,207 common shares and RSUs, including 44,922 shares of common stock and RSUs from current and prior awards.
Zurbay Donald reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Donald Zurbay received a grant of 28,261 restricted stock units (RSUs) under the company’s Non-Employee Director Compensation Program. The award value is approximately $130,000, based on the closing price of the common stock on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, as long as Zurbay continues serving on the board through that date. After this grant, he has a total reported position of 193,613 shares and rights, including common shares, unvested RSUs, and stock options exercisable within 60 days.
Mazzacco Catherine reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Catherine Mazzacco received an equity grant as board compensation. She was awarded 28,261 restricted stock units (RSUs) of common stock on June 4, 2026 at no cash cost, equal to approximately $130,000 based on the closing price that day.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders, subject to her continued service on the board. After this grant, she holds 69,276 shares and RSUs directly, and 37,492 shares indirectly through an irrevocable trust where she is the beneficiary.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported a sale of 12,728 shares of Common Stock on May 18, 2026 at a weighted average price of $5.12 per share. According to the disclosure, these shares were sold to cover her tax liability arising from recently vested restricted stock units.
After this tax-related sale, Bauerlein directly holds 688,893 shares, which includes 169,810 shares of Common Stock and 519,083 shares that are scheduled to be issued as her remaining RSUs vest and settle over time.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported an open-market sale of 7,231 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. According to the disclosure, the shares were sold to cover his tax liability tied to recently vesting restricted stock units.
Following this tax-related sale, Rodberg directly holds a total of 230,939 shares of common stock, including 47,160 currently held shares and 183,779 additional shares that will be acquired upon future vesting and settlement of restricted stock units. The transaction represents a small portion of his overall equity position.
Sight Sciences, Inc. Chief Legal Officer Jeremy B. Hayden sold 13,761 shares of common stock on April 6, 2026 at a weighted average price of $3.55 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this tax-related sale, he held a total of 369,770 shares, including 87,274 shares of common stock and 282,496 additional shares that will be received upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Chief Operating Officer Alison Bauerlein reported an open-market sale of 25,874 shares of common stock at a weighted average price of $3.48 per share. According to the filing, these shares were sold to cover her tax liability arising from the vesting of restricted stock units.
After this transaction, Bauerlein holds 701,621 shares of common stock, including 156,788 shares currently held and 544,833 shares that will be acquired upon the future vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported an open-market sale of 8,168 shares of Common Stock at a weighted average price of $3.48 per share. According to the footnotes, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi's reported holdings total 1,990,290 shares, consisting of 1,804,359 shares of common stock and 185,931 shares that will be acquired upon future vesting and settlement of restricted stock units. The sale represents a small portion of his overall position.
Sight Sciences EVP Taylor Brenton sold 2,869 shares of Common Stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold solely to cover tax liabilities arising from the vesting of restricted stock units, rather than as a discretionary portfolio move.
After this tax-related sale, Brenton holds 267,807 shares, including 31,631 shares of Common Stock and 236,176 additional shares that are scheduled to be received upon future vesting and settlement of RSUs. This indicates the transaction affected only a small portion of his overall equity exposure to the company.
Sight Sciences, Inc. President and CEO Paul Badawi sold 29,244 shares of common stock at a weighted average price of $3.70 per share. According to the disclosure, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
The shares were sold in multiple transactions at prices ranging from $3.63 to $3.85. After this tax-related sale, Badawi directly holds 5,544,983 shares of common stock and has an additional 606,173 shares that will be received upon future vesting and settlement of RSUs.
Sight Sciences, Inc. Chief Technology Officer David Badawi exercised previously granted stock options for 21,270 shares of common stock at $0.23 per share. These options were awarded under the company’s equity incentive plan and fully vested by January 1, 2020.
Following this option exercise, Badawi directly holds a total of 1,998,458 common share equivalents, consisting of 1,795,520 shares of common stock and 202,938 shares that will be received upon the future vesting and settlement of restricted stock units.
Sight Sciences, Inc. disclosed that Chief Technology Officer and director David Badawi received a grant of 64,915 restricted stock units (RSUs) on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is based on $420,000 divided by the closing price of Sight Sciences common stock on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. After this grant, Badawi beneficially owns 1,977,188 common shares, including 1,774,250 shares and 202,938 unvested RSUs that may settle into additional shares over time.
Sight Sciences, Inc. reported that Chief Legal Officer Jeremy B. Hayden received an award of 115,920 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan, at a price of $0 per share.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. Each RSU converts into one share of common stock. After this grant, Hayden beneficially owns 383,531 shares, including 75,562 shares of common stock and 307,969 shares underlying unvested RSUs.
Sight Sciences Chief Operating Officer Alison Bauerlein received a grant of 127,512 restricted stock units (RSUs) of common stock on February 3, 2026. The RSU award size is based on $825,000 divided by the closing price of the stock on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on continued service. After this grant, Bauerlein beneficially owns 727,495 shares of common stock, including 135,620 shares and 591,875 shares underlying unvested RSUs.
Sight Sciences reported that President and CEO Paul Badawi received a grant of 154,560 restricted stock units on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant’s size is based on a $1,000,000 value divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Badawi’s continued service. Following this award, he beneficially owns 6,180,400 shares of common stock, including 662,622 shares underlying unvested RSUs.
Sight Sciences Chief Financial Officer James Rodberg received a grant of 86,940 restricted stock units (RSUs) of common stock on February 3, 2026 under the company’s 2021 Incentive Award Plan. The grant value is set at $562,500, divided by the stock’s closing price on the grant date.
The RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on Rodberg’s continued service. Each RSU converts into one share of common stock upon vesting. After this award, he beneficially owns 238,170 shares, including 198,719 unvested RSUs and 39,451 vested shares.
Sight Sciences executive Brenton Taylor reported a new equity award. As EVP, Operations & R&D, he received 100,464 restricted stock units (RSUs) on February 3, 2026 under the company’s 2021 Incentive Award Plan, recorded as an acquisition of common stock at a price of $0 per share.
The grant size is based on dividing $650,000 by the closing price of Sight Sciences common stock on the grant date. These RSUs vest in 16 equal quarterly installments from March 31, 2026 through December 31, 2029, contingent on his continued service. After this award, he beneficially owns 270,676 shares, including 26,606 shares of common stock and 244,070 shares that will be acquired upon future RSU vesting and settlement.
Sight Sciences, Inc. director and Chief Technology Officer David Badawi reported a small insider sale of company stock. On January 16, 2026, he sold 4,836 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability in connection with the vesting of restricted stock units.
After this transaction, Badawi beneficially owns a total of 1,912,273 shares of Sight Sciences common stock, consisting of 1,774,250 shares of common stock and 138,023 shares that will be acquired upon the vesting and settlement of unvested restricted stock units.
Sight Sciences, Inc. Chief Financial Officer James Rodberg reported a small sale of company stock on January 16, 2026. He sold 2,616 shares of common stock at a weighted average price of $6.62 per share to cover his tax liability arising from the vesting of restricted stock units. The shares were sold in multiple trades at prices ranging from $6.44 to $6.69.
After this transaction, Rodberg beneficially owned 151,230 shares, consisting of 39,451 shares of common stock and 111,779 shares that will be received upon future vesting and settlement of restricted stock units.
Sight Sciences, Inc. President and CEO Paul Badawi, who is also a director and 10% owner, reported selling 22,362 shares of common stock on January 16, 2026 at a weighted average price of $6.62 per share. According to the filing, these shares were sold to cover his tax liability arising from the vesting of restricted stock units.
After this transaction, Badawi beneficially owns 6,025,840 shares of Sight Sciences common stock. This total includes 5,517,778 shares of common stock and 508,062 shares that will be received upon the vesting and settlement of unvested RSUs. The balance also corrects prior Form 4 reports by adding previously omitted RSUs and excluding certain stock option shares that were mistakenly included earlier.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 6,308 shares of the company’s common stock on January 16, 2026 at a weighted average price of $6.62 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale. Following this transaction, he beneficially owns 267,611 shares, consisting of 75,562 shares of common stock and 192,049 shares that will be received upon vesting and settlement of unvested RSUs. The filing also clarifies prior reporting by adding 39,825 previously omitted RSU shares and removing 11,326 stock option shares that had been inadvertently included in an earlier balance.
Sight Sciences, Inc. insider activity: President, CEO, director and 10% owner Paul Badawi reported two sales of the company’s common stock. On January 2, 2026, he sold 25,356 shares at a weighted average price of $7.43 per share, and on January 6, 2026, he sold 11,870 shares at a weighted average price of $7.48 per share.
According to the footnotes, the January 2 sale reflects shares sold to cover his tax liability arising from the vesting of restricted stock units. Both trades were executed in multiple transactions within disclosed price ranges. After these transactions, Badawi beneficially owned 5,925,276 shares of Sight Sciences common stock directly.
Sight Sciences Chief Operating Officer Alison Bauerlein reported two open-market sales of company common stock. On January 5, 2026, she sold 10,896 shares at a weighted average price of $7.82 per share, and on January 6, 2026, she sold 9,647 shares at a weighted average price of $7.48 per share.
According to the footnotes, these sales were made to cover her tax liability arising from the vesting of restricted stock units, meaning they were linked to equity compensation rather than a discretionary reduction in holdings. After these transactions, she beneficially owned 599,983 shares of Sight Sciences common stock directly.
Sight Sciences executive Brenton Taylor, EVP of Operations & R&D, reported a small sale of company stock mainly to cover taxes from vesting equity. On January 6, 2026, he sold 619 shares of Sight Sciences common stock at a weighted average price of $7.48 per share, through multiple trades priced between $7.39 and $7.67. After this tax-related sale, he directly holds 170,212 shares of the company’s common stock.
Sight Sciences director and 10% owner Staffan Encrantz reported an open-market purchase of 13,958 shares of common stock on 12/16/2025 at a weighted average price of $8.308 per share. The shares were bought in multiple trades at prices ranging from $8.12 to $8.40.
After this transaction, Encrantz directly beneficially owns 1,391,922 shares, which include 30,952 restricted stock units subject to vesting. He is also reported as having indirect beneficial ownership of 632,456 shares held by a revocable trust where he serves as trustee, and 5,086,920 shares held by Allegro Investment Fund, L.P., although he disclaims pecuniary interest and beneficial ownership in the Allegro-held shares.
Sight Sciences, Inc. (SGHT) reported an insider transaction by its EVP, Operations & R&D, Brenton Taylor. On 11/17/2025, Taylor sold 14,418 shares of common stock at a weighted average price of $7.06 per share. According to the footnotes, the sale was made to cover his tax liability arising from the vesting of restricted stock units. After this transaction, Taylor beneficially owned 170,831 shares of Sight Sciences common stock.
Sight Sciences, Inc. (SGHT) filed a Form 4 reporting equity transactions by Chief Legal Officer Jeremy Hayden. On 11/12/2025, he exercised stock options for 2,440 shares of common stock at $1.96 per share and an additional 710 shares at the same exercise price, all under the company’s equity incentive plan.
The same day, 3,150 shares of common stock were sold at a weighted average price of $8.01 per share, in multiple trades between $8.00 and $8.06. Following these transactions, Hayden beneficially owned 256,590 shares of common stock directly. The filing states the transactions were made under a Rule 10b5-1 trading plan tied to a marital separation agreement, and that his former spouse will receive all proceeds from the share sales.
Sight Sciences (SGHT) reported an insider equity grant. Chief Operating Officer Alison Bauerlein acquired 23,006 RSUs on November 11, 2025 under the company’s 2021 Incentive Award Plan at a stated price of $0 per unit. The award equals approximately $150,000 of common stock based on the grant-date price, with each RSU representing one share.
The RSUs vest in 16 equal quarterly installments from December 31, 2025 through September 30, 2029, contingent on continued service. Following this grant, Bauerlein beneficially owned 620,526 shares directly.
Sight Sciences (SGHT) disclosed a Form 4 for its Chief Financial Officer, reporting an equity award tied to service. On November 11, 2025, the officer acquired 15,337 shares of common stock at $0, reflecting settlement of a new grant of restricted stock units (RSUs) under the company’s 2021 Incentive Award Plan. Following the transaction, the officer beneficially owns 161,363 shares, held directly.
The RSU grant equals approximately $100,000 of common stock based on the grant-date price and vests in 16 equal quarterly installments from December 31, 2025 through September 30, 2029. Each RSU represents the right to receive one share of common stock and has no expiration date.
Sight Sciences, Inc. reporting person Brenton Taylor disclosed a sale of 591 shares of common stock on 10/06/2025. The sale was executed to cover the reporting person's tax liability related to the vesting of restricted stock units and occurred in multiple transactions at prices ranging from $3.32 to $3.45, with a weighted average price of $3.37. After the reported sale, the reporting person beneficially owned 185,249 shares, held directly. The form bears a signature date of 10/08/2025.
Sight Sciences (SGHT) disclosed an insider transaction by its Chief Financial Officer. On 10/02/2025, the officer reported a sale of 19,948 shares of common stock at $3.3 per share, coded “S.” Following the transaction, the officer directly holds 597,520 shares.
The filing notes the shares were sold to cover the reporting person’s tax liability associated with the vesting of restricted stock units. This reflects a routine tax-related disposition rather than a discretionary portfolio trade.
Sight Sciences (SGHT) President & CEO, Director, and 10% owner Paul Badawi reported a sale of common stock on 10/01/2025. He sold 24,441 shares at $3.34 per share (Code S), as noted in the filing’s footnote, to cover tax liabilities arising from the vesting of restricted stock units.
Following this transaction, Badawi beneficially owns 5,962,502 shares of Sight Sciences common stock directly. The filing indicates the disposition was related to tax withholding tied to equity compensation vesting.
David Badawi, Chief Technology Officer and director of Sight Sciences, Inc. (SGHT), reported a sale of 6,033 shares of common stock on 10/03/2025 at a price of $3.27 per share. The filing states the shares were sold to cover the reporting person's tax liability from the vesting of restricted stock units. After the sale, Mr. Badawi beneficially owned 1,864,992 shares of common stock.